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Abstract
Patients who have already suffered a vascular event require more and better control of cardiovascular risk
factors. Different atherogenic indexes such as TC/HDLc, LDLc/HDLc, apoB/apoA-I, LDLc/apoB and non-HDLc/HDLc
have been used to follow-up the patients because of their predictive capacity of the lipid profile. The aim of this study
was to evaluate atherogenic ratios as a marker of the lipid residual risk in high-risk patients receiving statin therapy
and to know the changes produced by previous lipid-lowering drugs treatment for a previous coronary event.
The study including patients admitted to coronary care units of six Spanish tertiary hospitals for Acute Coronary
Syndrome (ACS). A total of 633 ACS patients were included; of these, 478 (75.8%) had presented a myocardial
infarction and 153 (24.2%) angina. A previous ACS had occurred in 43.1% of cases, and was the first episode in
56.9% of the studied patients.
Among patients with known ischemic heart disease, 187 (52.2%) were receiving lipid-lowering drugs, mainly
statins (182 patients, 50.7%). Of those with a first ACS, 59 (21.7%) were on lipid-lowering drugs: 55 (20.1%) statins
and 4 (1.7%) fibrates. Patients with recurrent ACS had similar triglyceride and HDLc levels, but significantly lower
total cholesterol and LDLc concentrations compared with those presenting the first ACS. Patients with recurrent ACS
had significantly lower non-HDLc levels, TC/HDLc and LDLc/HDLc, but higher HDLc/TC and HDLc/LDLc ratios
compared with first ACS patients.
In patients taking statins the lipid residual vascular risk was related with the persistence of cardiovascular risk
factors, and related with lipid profile with dyslipemia no-LDL dependent. So, we can conclude that the correction of
lipid profile by statin is not per se sufficient to control cardiovascular risk.
Introduction
Cardiovascular disease is the major cause of premature death in
Spain, as in other western countries, and underlies a great deal of
disability. Consequently, patients who have already suffered a vascular
event require more and better risk control [1]. Although low-density
lipoprotein cholesterol (LDLc) is the traditional marker for
cardiovascular risk and monitoring of statin therapy, it has been
emphasized that cardiovascular disease management based exclusively
on this lipid parameter might not be sufficient [2,3]. For this reason,
therapeutic guidelines, though based on LDLc as the principal target of
lipid-lowering therapy, also consider other lipid factors like non High-
Density Lipoprotein cholesterol (HDLc), apoprotein (apo) B, apo A-I
and the total cholesterol (TC)/HDLc, some of which can be better
predictors of cardiovascular risk than LDLc alone [4,5]. However,
debate on the choice of the best lipid parameter has intensified, with
apparently conflicting evidence among prospective studies [6-8].
Different atherogenic indexes such as TC/HDLc, LDLc/HDLc,
apoB/apoA-I, LDLc/apoB and non-HDLc/HDLc have been defined in
an attempt to optimize the predictive capacity of the lipid profile [9],
the efficiency of which has been demonstrated [10-12]. Although these
indexes can provide information on risk factors difficult to quantify by
routine analysis, and could better mirror the metabolic and clinical
interactions among lipid fractions, they are under-used in
cardiovascular disease prevention.
Thus, the aim of the present study was to establish atherogenic
ratios, as a marker of the atherogenicity/anti-atherogenicity balance in
patients with high vascular risk receiving statin therapy, for detecting
the treatable residual risk. To this end, in a cohort of Spanish patients
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hospitalized with Acute Coronary Syndromes (ACS), patients
presenting the first episode are compared with those with previous
ischemic heart disease. This study will further evaluate the changes
produced by previous treatments and highlight the residual risk these
patients still have, even while still on lipid-lowering therapy for a
previous coronary event.
Material and Methods
Medical records of patients admitted to coronary care units of 6
Spanish tertiary hospitals for ACS between January 2004 and
September 2007 were selected based on the following inclusion
criteria: a) availability of lipid profile at admission, including total
cholesterol, triglycerides and HDLc, and b) lipid-lowering drugs prior
to admission. ACS was defined according to European/American
recommendations [13,14]. Age, sex, anthropometric parameters,
smoking status (classified as non-smoker, smoker and ex-smoker),
hypertension and type-2 diabetes were retrospectively assessed from
the clinical records. A total of 633 ACS patients were included in the
study. Of these, 478 (75.8%) had presented a myocardial infarction
and 153 (24.2%) angina. A previous ACS had occurred in 43.1% of
cases, and was the first episode in 56.9%.
LDLc concentration was calculated by the Friedewald formula [15].
The different atherogenic indexes analyzed in each patient were: non-
HDLc, TC/HDLc, LDLc/HDLc, HDLc/TC, HDLc/LDLc and log
(triglycerides/HDLc). The study was authorized by the corresponding
Clinical Research Ethics Committees of the participating centres.
Statistical analyses were made with the chi-square test and the
Fisher’s exact test for categorical variables and the ANOVA test to
study the differences among variables. A p value <0.05 was considered
statistically significant. All statistical analyses were performed using
the Statistical Package for Social Sciences (SPSS) for Windows
software, v. 11.5; Chicago, Illinois, United States.
Results
Of the 633 patients studied, 505 (79.8%) were men and 128 (20.2%)
women. Clinical characteristics of the study population are
summarized in Table 1. Patients with recurrent ACS were significantly
younger, fewer were smokers, and had a higher percentage of
hypertension and type-2 diabetes, with angina being the most
common presentation form of ACS compared with those suffering a
first episode.
Among patients with known ischemic heart disease, 187 (52.2%)
were receiving lipid-lowering drugs, mainly statins (182 patients,
50.7%) and, more rarely, fibrates (5 patients, 2.6%). Of those with a
first ACS, 59 (21.7%) were on lipid-lowering drugs: 55 (20.1%) statins
and 4 (1.7%) fibrates.
Previous IHD
(n=274)
No previous
IHD (n=359)
p
Age, yrs 60.82 65.83 0.000 (1)
Sex: Male
Female
278 (82.8%)
81 (17.2%)
227 (77.4%)
47 (22.6%)
0.057 (1)
Tobacco: Smoker
Ex-smoker
Non-smoker
79 (29.3%)
124 (45.9%)
67 (24.8%)
169 (47.9%)
87 (24.6%)
97 (27.5%)
0.000 (2)
BMI, Kg/m2 28.23 28.55 0.380 (3)
Hypertension 193 (72.0%) 185 (52.0%) 0.000 (1)
Type 2 diabetes 1204 (4.3%) 81 (23.1%) 0.000 (1)
AMI as a manifestation of ACS 185 (68.3%) 297 (83.4%) 0.000 (1)
Angina as a manifestation of
ACS
92 (33.9%) 61 (17.1%) 0.000 (1)
Table 1: Characteristics of the 633 patients with acute coronary
syndrome, according to a history of ischemic heart disease. (1) Fisher
exact test, (2) chi-squared, (3) Anova test.
Patients with recurrent ACS had similar triglyceride and HDLc
levels, but significantly lower total cholesterol (TC) and LDLc
concentrations compared with those presenting the first ACS (Figure
1). So, these patients with recurrent ACS with lower TC and LDL, but
without changes on triglycerides and HDL, remains with a non-LDL-
cholesterol-dependent dyslipemia. When only the ACS patients
treated with statins were analyzed (Table 2), the lipid profile results
were identical. So, the correction of lipid profile by statin does not
eliminate the non-LDL-dependent dyslipemia.
Previous IHD No previous IHD p
TC (mg/dL) 172.1 (41.6) 203.0 (46.9) 0
LDLc (mg/dL) 110.2 (39.6) 136.4 (44.9) 0
HDLc (mg(dL) 40.0 (12.1) 38.9 (10.3) 0.394
TG (mg/dL) 145.8 (65.3) 171.8 (88.6) 0.144
Table 2: Lipid profile of ACS patients treated with statins, according to
a history of ischemic heart disease (IHD).
Figure 1: Lipid parameters in patients with acute coronary
syndrome according to a history of Ischemic Heart Disease (IHD).
Anova test.
The atherogenic ratios and significant differences can be found in
all indexes, except for log (triglycerides)/HDLc (Figure 2). Patients
with recurrent ACS had significantly lower non-HDLc levels, TC/
HDLc and LDLc/HDLc, but higher HDLc/TC and HDLc/LDLc ratios
compared with first ACS patients. Again, when the atherogenic index
profile was analyzed only in patients taking statins (Table 3), and
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despite an improvement in the atherogenic ratios, the same significant
differences persisted as in the overall group.
Previous IHD No previous IHD p
Non-HDLc (mg/dL) 131.9 (40.2) 164.1 (45.7) 0
TC/HDLc 4.55 (1.47) 5.49 (1.66) 0.001
LDLc/HDLc 2.95 (1.34) 3.70 (1.47) 0.005
HDLc/TC 0.24 (0.08) 0.20 (0.07) 0
HDLc/LDLc 0.42 (0.20) 0.33 (0.17) 0
Log (TG/HDLc) 0.41 (0.59) 0.59 (0.57) 0.067
Table 3: Atherogenic ratios in 633 ACS patients on statins, according
to a history of ischaemic heart disease.
Figure 2: Atherogenic indexes in patients with acute coronary
syndrome, according to a history of Ischemic Heart Disease (IHD).
Anova test.
Discussion
As can be gathered from the results of the present study, patients
with recurrent ACS, although the prevalence of smoking was lower,
had a considerable and significantly higher frequency of other major
risk factors such as hypertension and type-2 diabetes. Undoubtedly,
these risk factors also contribute to residual vascular risk [16].
With regard to the ischemic clinical form of presentation, the first
ACS event tended to be mainly myocardial infarction; however, angina
was the most frequent type of recurrent ACS, representing over a third
of these events.
Patients with recurrent ACS compared with those presenting a first
ACS showed a more favorable lipid profile, with lower total cholesterol
and LDLc and similar triglyceride and HDLc levels. These findings
were related to prior statin therapy more frequently reported in
patients with recurrent ACS. Statins are known to exert a powerful
LDLc-lowering effect, but have a marginal effect on the remaining
lipid parameters and therefore a residual vascular risk attributable to
elevated triglycerides and low HDLc may persist.
In the present study, all ratios in which TC or LDLc were
represented showed an improvement in patients on statins. No
difference was observed in the index related to triglycerides and HDLc
as these lipids were not modified since statin treatment had little effect
on such parameters. The triglyceride/HDLc index has been reported to
be highly predictive of a first ischemic heart disease eevent [17],
mainly in overweight patients or those with type-2 diabetes or
metabolic syndrome [18]. From the pharmacologic point of view,
statins do not appear to exert any effect on this index. Thus, a strategy
for reducing this index, such as the use of fibrates or nicotinic acid, can
help to attenuate the risks attributable to atherogenic dyslipidemia
(increase in triglycerides and decrease in HDLc) as already reported
[19,20].
Changes in the atherogenic indexes run parallel to modifications in
lipid profile and reflect the effects of lipid-lowering drugs. Since statins
are the most common hypolipemiant used, the un-modifiable
triglyceride and HDLc concentrations account for the residual
vascular risk in these patients. So, it has been suggested that there is
evidence for not using LDLc alone as the only target for the treatment
of patients with dyslipidaemia [21].
Patients treated with statins are especially significant with regards to
the persistence of triglyceride above and HDLc below the objectives
established as therapeutic objectives and (150 mg/dL for triglycerides
and 40 mg/dl for HDLc) for high-risk patients who have suffered an
episode of ischaemic heart disease [22].
The significant decrease of total cholesterol and LDLc is
accompanied by a significant decrease in atherogenic indices in
patients with recurrent ACS. However, despite this improvement, new
ischaemic events occur. In other words, despite a standard
management of LDLc, a recurrence of ACS occurs in hyper-
triglyceridemic and low HDLc patients. This fact has been recently
described in patients with acute coronary syndrome [23], although
they had not been compared –as in our study- a population with and
without a history of coronary episodes. The use of indices like
coronary disease predictors has evidenced that, exactly, the simplest
parameters that can be used (like total cholesterol and HDLc) have the
same predictive power as others that are more complex, which include
apoproteins [24]. In patients taking statins the absolute risk reduction
does not eliminate residual risk; and the low HDLc that is found in
patients with acute coronary syndrome [25] could play an important
role to increase residual cardiovascular risk [26] a despite of others
cardiovascular risk factors. Our study is focused on lipid profile and
show the persistent dyslipemia non-LDL-cholesterol related.
The modifications in those ratios are sensitive to taking statins, in a
way that those patients with a history of ischaemic heart disease and
taking of statins improve their atherogenic indices thanks to the
improvement of cholesterol figures and LDLc without modifying the
triglycerides and HDLc. It is a key feature that the statin therapy is not
sufficient to control global dyslipidemia a despite his effects on LDL-
cholesterol. This is the main concept around of residual vascular risk.
The atherogenic indices accurately and simply reflect the changes in
the lipid profile, but are more expressive in detailing the persistence of
residual lipid risk given that in such indices, lipid fractions that are not
modified with standard treatment together with those that are
modified by the previous lipid-lowering treatment, are included. This
phenomenon is particularly significant in patients with recurrent ACS.
This is characteristic in patients with successive episodes of
ischaemic heart disease. In other words, the risk of a coronary episode
continues even improving some lipid parameters as well as the
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atherogenic indices, and this is because of the persistence of such
factors.
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